Results 231 to 240 of about 237,523 (354)

Persistently low blood eosinophils identify a high-risk phenotype in COPD. [PDF]

BMC Pulm Med
Zhang W, Chew SY, He X, Wu Y, Koh MS, Wang G, Xu Z, Tiew PY.   +7 more
europepmc   +1 more source

Intraosseous sarcoidosis imitating peri‐implantitis: A case study

Clinical Advances in Periodontics, EarlyView.
Abstract Background Sarcoidosis is a multisystem granulomatous disorder of unknown cause, typically affecting the lungs and lymph nodes, but it can also involve the eyes, skin, heart, bones, and other organs. The exact cause is unclear, but genetic factors and environmental triggers like infections, chemicals, or dust may play a role.
Magdalena Orlowska, David S. Gottlieb, Kenneth S. Kornman   +2 more
wiley   +1 more source

Eosinophilic Organ Complications Associated with Dupilumab Therapy - Narrative Review and Current Evidence. [PDF]

J Asthma Allergy
Suter P, Buetler VA, Graf N, Pavlov N.
europepmc   +1 more source

How to Reduce Wheat Allergens and FODMAPs in Foods: A Critical Review of Patents

Cereal Chemistry, EarlyView.
ABSTRACT Background and Objectives Supported by scientific evidence, this critical review of the patent literature examined methods to reduce wheat allergens and FODMAPs in foods, which may trigger digestive disorders and other health problems. The following topics were covered: proteolytic enzymes, proteolytic bacteria and yeasts, separation, plant ...
Pierre Gélinas, Jérémie Théolier
wiley   +1 more source

Proton pump inhibitors modulate esophageal epithelial barrier function and crosstalk with eosinophils. [PDF]

Pediatr Allergy Immunol
Gautam R, Lal M, Carroll MC, Mrozek Z, Trachsel T, Beers J, Ruffner MA.   +6 more
europepmc   +1 more source

Reductions in eosinophil biomarkers by benralizumab in patients with asthma.

Respiratory Medicine, 2016
Tuyet-Hang Pham, G. Damera, P. Newbold, K. Ranade   +3 more
semanticscholar   +1 more source

Population Pharmacokinetics of Dupilumab in Adults, Adolescents, and Children With Eosinophilic Esophagitis

Clinical Pharmacology &Therapeutics, EarlyView.
Dupilumab, a fully human monoclonal antibody that blocks key drivers of type 2 inflammation, is approved across 8 diseases, including eosinophilic esophagitis. Subcutaneous dupilumab 300 mg weekly improved outcomes vs. placebo in adults (aged ≥ 18 years) and adolescents (aged ≥ 12 to < 18 years) during the phase III LIBERTY EoE TREET study (NCT03633617)
Jenny‐Hoa Nguyen, Mirna Chehade, Evan S. Dellon, Allen Radin, Jason Chittenden, Mohamed A. Kamal, Margee Louisias, Christine Xu, Matthew P. Kosloski   +8 more
wiley   +1 more source

Intravenous Lipopolysaccharide Challenge in Healthy Participants Reveals Pharmacodynamic Markers in Blood and Bone Marrow for Early‐Phase Oncology Drug Development

Clinical Pharmacology &Therapeutics, EarlyView.
Demonstrating pharmacological effects in early‐phase oncology clinical trials remains challenging, largely due to the lack of robust pharmacodynamic markers. Lipopolysaccharide (LPS) is used as an immune challenge agent in healthy participants to study drugs for autoimmune conditions.
Igor Radanović, Ingrid Tomljanović, Wieke H. Grievink, Diana R. Pereira, Michelle Osse, Peter van Balen, Maria J. Juachon, Marieke L. de Kam, Lisa Pagan, Manon A.A. Jansen, Matthijs Moerland, Jacobus J. Bosch   +11 more
wiley   +1 more source

Surface expression of CD63 and HLA-DR in circulating eosinophils correlates with improved clinical control after treatment optimization in asthma. [PDF]

Sci Rep
Scarlata S, Mazzuca C, Vitiello L, Finamore P, Coppola A, Maurizi F, Travaglini S, Zito A, Fontana D, Incalzi RA.   +9 more
europepmc   +1 more source

The Peripheral Blood Eosinophil Proteome.

Journal of Proteome Research, 2016
Emily M. Wilkerson, M. Johansson, Alexander S. Hebert, M. Westphall, S. Mathur, N. Jarjour, Elizabeth A. Schwantes, D. Mosher, J. Coon   +8 more
semanticscholar   +1 more source